Revolution Medicines COO sells 4,967 shares

Q: What insider transaction did RVMD report for COO Margaret A. Horn?

RVMD reported that COO Margaret A. Horn sold a total of 4,967 shares of common stock on September 16, 2026 in open‑market transactions executed under a pre‑arranged Rule 10b5-1 instruction letter.

Q: At what prices did the RVMD insider sales occur on September 16, 2026?

The filing shows one sale of 76 shares at a weighted average price of $195.01 per share, with individual trades between $195.00 and $195.03, and another sale of 4,891 shares at $199.30 per share.

Q: How many RVMD shares did the COO sell in total in this Form 4?

The COO sold a combined total of 4,967 shares of Revolution Medicines common stock, consisting of 76 shares in one transaction and 4,891 shares in a second transaction, both dated September 16, 2026.

Q: What restricted stock unit position is referenced for the RVMD COO?

A footnote states that a reported holding includes 56,713 restricted stock units, indicating a significant equity-based compensation position in addition to common stock.

Revolution Medicines’ COO reports pre-planned stock sales to cover taxes on vested restricted stock units.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) reported that Chief Operating Officer Margaret A. Horn sold a total of 4,967 shares of common stock on September 16, 2026 in open‑market transactions. The sales were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy her tax withholding obligation upon the vesting of restricted stock units.

The transactions included 76 shares at a weighted average price of $195.01 (with individual trades ranging from $195.00 to $195.03) and 4,891 shares at $199.30 per share. A related holding reported in the filing includes 56,713 restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 4,967 shares

Net Sell 2 txns

Insider Horn Margaret A

Role Chief Operating Officer

Sold 4,967 shs ($990K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	76	$195.0083	$15K
Sale	Common Stock ^{F1, F3}	4,891	$199.3032	$975K

Holdings After Transaction: Common Stock — 149,680 shares (Direct)

Footnotes (3)

F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
F2. The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3. Includes 56,713 restricted stock units.

Key Figures

Shares sold (total): 4,967 shares First tranche sold: 76 shares First tranche price range: $195.00–$195.03 per share +3 more

6 metrics

Shares sold (total) 4,967 shares Total common shares sold by the COO on September 16, 2026

First tranche sold 76 shares Common stock sold at a weighted average price of $195.01 per share

First tranche price range $195.00–$195.03 per share Price range for the 76-share sale; weighted average $195.01

Second tranche sold 4,891 shares Common stock sold at $199.30 per share

Restricted stock units referenced 56,713 units Holding noted as including 56,713 restricted stock units

Rule 10b5-1 instruction letter adoption date May 31, 2023 Plan governing these sales adopted on this date

Key Terms

Rule 10b5-1 instruction letter, restricted stock units, weighted average sale price, tax withholding obligation

4 terms

Rule 10b5-1 instruction letter regulatory

"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023"

restricted stock units financial

"Includes 56,713 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price."

tax withholding obligation financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD report for COO Margaret A. Horn?

RVMD reported that COO Margaret A. Horn sold a total of 4,967 shares of common stock on September 16, 2026 in open‑market transactions executed under a pre‑arranged Rule 10b5-1 instruction letter.

At what prices did the RVMD insider sales occur on September 16, 2026?

The filing shows one sale of 76 shares at a weighted average price of $195.01 per share, with individual trades between $195.00 and $195.03, and another sale of 4,891 shares at $199.30 per share.

How many RVMD shares did the COO sell in total in this Form 4?

The COO sold a combined total of 4,967 shares of Revolution Medicines common stock, consisting of 76 shares in one transaction and 4,891 shares in a second transaction, both dated September 16, 2026.

Were the RVMD insider sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, indicating they were pre‑arranged rather than discretionary trades.

What was the purpose of the RVMD COO’s stock sales disclosed in this filing?

According to the footnote, the sales were made to satisfy the COO’s tax withholding obligation upon the vesting of restricted stock units, rather than as discretionary portfolio sales.

What restricted stock unit position is referenced for the RVMD COO?

A footnote states that a reported holding includes 56,713 restricted stock units, indicating a significant equity-based compensation position in addition to common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/18/2026 - 06:03 PM Accepted by SEC EDGAR 09/18/2026 - 06:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horn Margaret A

(Last)

(First)

(Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/16/2026		S⁽¹⁾		76	D	$195.0083⁽²⁾	154,571	D
Common Stock	09/16/2026		S⁽¹⁾		4,891	D	$199.3032	149,680⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

2. The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 56,713 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Margaret A. Horn	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Revolution Medicines COO sells 4,967 shares

Rhea-AI Filing Summary

Positive

Negative